Last week South Duvall and Sagamore Ventures announced that they have formed a partnership to bring more than 100,000 square feet of high-end laboratory space to City Garage in Baltimore’s Port Covington over the next ten years. Approximately 75,000 square feet of space is set to be delivered in the next year alone.
South Duvall and Sagamore Ventures to Bring Life Science to City Garage
Published on :South Duvall and Sagamore Ventures today announced a partnership to bring more than 100,000 square feet of biotech laboratory space to City Garage in Port Covington, Baltimore, over the next ten years, with approximately 75,000 square feet being delivered in the next year.
Catalent Invests Additional $230 Million to Expand its State-of-the-Art Gene Therapy Commercial Manufacturing Campus in Harmans, Maryland
Published on :Catalent Invests Additional $230 Million to Expand its State-of-the-Art Gene Therapy Commercial Manufacturing Campus in Harmans, Maryland
University of Maryland, Baltimore (UMB) Grants Pumas-AI Exclusive License of Analytics Platform to Enhance Drug Development
Published on :Pumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to enhancements to Pumas, an end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development lifecycle. Pumas 2.0 builds on the company’s existing platform, which also employs technology licensed from UMB.
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
Published on :Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.
The Storied 25 Year History Behind the Baltimore Biotech Manufacturing Facility Producing COVID-19 Vaccines
Published on :Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines. However, the history of this facility goes back more than two decades.
Baltimore’s CoapTech Receives CE Mark Approval and CPT Procedure Code for Its PUMA-G System
Published on :CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today it has received CE Mark certification, as well as an approved CPT Procedure Code for its PUMA-G System, the world’s first and only ultrasound gastrostomy system that allows physicians to place gastrostomy tubes at the point of care, using solely ultrasound imaging.
Baltimore’s Port Covington Project Looks To Life Sciences
Published on :Developers of Baltimore’s Port Covington project are focusing on life sciences development, including a forthcoming project from Alexandria Real Estate.
Port Covington developers look to create nationally known biotech hub in South Baltimore
Published on :As the first buildings at Port Covington begin to rise, the project’s developers have a vision for the mini-city sprouting on a South Baltimore peninsula as the nation’s next big biotech hub.
Early Charm Announces Hiring of Dan Keeley to Lead Newly Formed Lankenau Ventures
Published on :Early Charm, a venture studio that converts science to business, today announced the hiring of Dan Keeley to lead Lankenau Ventures, a new joint venture with Early Charm that aims to accelerate development and commercialization of medical inventions conceived by frontline healthcare workers.